Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas

Conclusions: OD and AIM did not differ with respect to either OS or PFS. Although this study’s size initially appeared the most likely explanation, lack of significant activity of olaratumab was subsequently reported in the phase III trial of OD. Our results suggest that future conditional oncology drug approvals should be accompanied by mandated registries to monitor outcomes of patients treated after conditional approval, but before full approval.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Soft Tissue Source Type: research